Assessing Allogeneic Chondroprogenitor Manufacture Under Good Manufacturing Practice (GMP) Serum Free And Xeno-Free Conditions. (2023)

First Author: Perry J
Attributed to:  Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.joca.2023.01.223

Publication URI: http://dx.doi.org/10.1016/j.joca.2023.01.223

Type: Journal Article/Review

Parent Publication: Osteoarthritis and Cartilage